Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina

Journal of the American College of Cardiology

Volumn 43, Issue 8, 2004, Pages 1375-1382

  Chaitman, Bernard R ^a,i   Skettino, Sandra L ^b   Parker, John O ^c   Hanley, Peter ^d   Meluzin, Jaroslav ^e   Kuch, Jerzy ^f   Pepine, Carl J ^g   Wang, Whedy ^b   Nelson, Jeanenne J ^h   Hebert, David A ^h   Wolff, Andrew A ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CV THERAPEUTICS INC   (United States)

^c KINGSTON GENERAL HOSPITAL   (Canada)

^d IN Elkhart Clinic   (United States)

^e ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

^g UNIVERSITY OF FLORIDA   (United States)

^h IQVIA   (United States)

ⁱ SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Analysis of variance; ANOVA; Blood pressure; BP; CARISA; Combination Assessment of Ranolazine In Stable Angina trial; ECG; Electrocardiogram electrocardiographic; ETT; Exercise treadmill test; Heart rate; HR; MARISA

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOHYDRATE; DIGOXIN; FATTY ACID; NITRIC ACID DERIVATIVE; OXYGEN; PLACEBO; RANOLAZINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASTHENIA; BLOOD LEVEL; BLOOD PRESSURE; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE; EXERCISE TEST; FEMALE; FOLLOW UP; HEADACHE; HEART MUSCLE ISCHEMIA; HEART RATE; HEMODYNAMICS; HIGH RISK POPULATION; HUMAN; HYPERHIDROSIS; MALE; MONOTHERAPY; NAUSEA; OXIDATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; STRESS; SURVIVAL RATE; SURVIVAL TIME; SUSTAINED DRUG RELEASE; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 11144356285     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.11.045     Document Type: Article

References (40)

1. Wolff A.A., Rotmensch H.H., Stanley W.C., Ferrari R. Metabolic approaches to the treatment of ischemic heart disease The clinicians' perspective. Heart Fail Rev. 7:2002;187-203.
2. Clarke B., Wyatt K.M., McCormack J.G. Ranolazine increases active pyruvate dehydrogenase in perfused rat hearts Evidence for an indirect mechanism. J Mol Cell Cardiol. 28:1996;341-350.
3. McCormack J.G., Barr R.L., Wolff A.A., Lopaschuk G.D. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 93:1996;135-142.
4. Allely M.C., Alps B.J., Kilpatrick A.T. The effects of the novel anti-anginal agent RS-43285 on [lactic acid], [K+] and pH in a canine model of transient myocardial ischemia. Biochem Soc Trans. 15:1987;1057-1058.
5. Ferrandon P., Pascal J.-C., Armstrong J.M. Protective effects of the novel anti-ischemic agent ranolazine (RS-43285) in perfused rat hearts. Br J Pharmacol. 93:(Suppl):1988;247P.
6. Allely M.C., Alps B.J. Prevention of myocardial enzyme release by ranolazine in a primate model of ischemia with reperfusion. Br J Pharmacol. 99:1990;5-6.
7. Ferrandon P., Chaylat C., Fligiel E., Armstrong J.M. Ranolazine but not allopurinol or dipyridamole reduces the ventricular acidosis and lactate produced by low perfusion flow in isolated rat hearts. Therapie. 45:1990;10.
8. Clarke B., Spedding M., Patmore L., McCormack J.G. Protective effects of ranolazine in guinea-pig hearts during low-flow ischemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol. 109:1993;748-750.
9. Gralinski M.R., Black S.C., Kilgore K.S., Chou A.Y., McCormack J.G., Lucchesi B.R. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 28:1994;1231-1237.
10. Gralinski M.R., Chi L., Park J.L., et al. Protective effects of ranolazine on ventricular fibrillation induced by activation of the ATP-dependent potassium channel in rabbit heart. J Cardiovasc Pharmacol Ther. 1:1996;141-148.
11. Matsumura H., Hara A., Hashizume H., Maruyama K., Abiko Y. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart Comparison with dichloroacetate. Jpn J Pharmacol. 77:1998;31-39.
12. Wang J.X., Maruyama K., Murakami M., Endo T., Komatsu H., Akahane M. Antianginal effects of ranolazine in various experimental models of angina. Arzneimittelforschung. 49:1999;193-199.
13. Zacharowski K., Blackburn B., Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 418:2001;105-110.
14. Cocco G., Rousseau M.F., Bouvy T., et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 20:1992;131-138.
15. Ranolazine Study Group, Pepine C.J., Wolff A.A. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol. 84:1999;46-50.
16. Sheffield LT. Exercise stress testing. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 3rd edition. Philadelphia, PA: WB Saunders Company, 1988;1:223-41
17. Caralis D.G., Shaw L., Bilgere B., et al. Application of computerized exercise ECG digitization. Interpretation in large clinical trials. J Electrocardiol. 25:1992;101-110.
18. Bauer P. Multiple testing in clinical trials. Stat Med. 10:1991;871-890.
19. Koch G.G., Gansky S.A. Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J. 30:1996;523-534.
20. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
21. Vetter N.J., Strange R.C., Adams W., Oliver M.F. Initial metabolic and hormonal response to acute myocardial infarction. Lancet. 1:1974;284-289.
22. Oliver M.F., Kurien V.A., Greenwood T.W. Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction. Lancet. 1:1968;710-715.
23. Mueller H.S., Ayres S.M. Metabolic responses of the heart in acute myocardial infarction in man. Am J Cardiol. 42:1978;363-371.
24. Rackley C.E., Russell R.O., Rogers W.J., Mantle J.A., McDaniel H.G., Papapietro S.E. Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am Heart J. 102:1981;1038-1049.
25. Sodi-Pallares D., Testelli M.R., Fishleder B.L., et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction A preliminary clinical report. Am J Cardiol. 9:1962;166-181.
26. Oliver M.F., Opie L.H. Effects of glucose and fatty acids on myocardial ischemia and arrhythmias. Lancet. 343:1994;155-158.
27. Fath-Ordoubadi F., Beatt K.J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo-controlled trials. Circulation. 96:1997;1152-1156.
28. ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group, Diaz R., Paolasso E.A., Piegas L.S., et al. Metabolic modulation of acute myocardial infarction The ECLA Glucose-Insulin-Potassium Pilot Trial. Circulation. 98:1998;2227-2234.
29. Brown M.J., Horowitz J.D., Mashford M.L. A double-blind trial of perhexiline maleate in the prophylaxis of angina pectoris. Med J Aust. 1:1976;260-263.
30. Bartels G.L., Remme W.J., Pillay M., Schönfeld D.H.W., Kruijssen D.A.C.M. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol. 74:1994;125-130.
31. Arterial Revascularization Therapies Study Group, Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 344:2001;1117-1124.
32. Minitran Efficacy Study Group, Parker J.O., Amies M.H., Hawkinson R.W., et al. Intermittent transdermal nitroglycerin therapy in angina pectoris Clinically effective without tolerance or rebound. Circulation. 91:1995;1368-1374.
33. ASIS Study Group, Stone P.H., Gibson R.S., Glasser S.P., et al. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. Circulation. 82:1990;1962-1972.
34. Carvedilol-Angina Study Group, Weiss R., Ferry D., Pickering E., et al. Effectiveness of three different doses of carvedilol for exertional angina. Am J Cardiol. 82:1998;927-931.
35. Klinke W.P., Baird M., Juneau M., et al. Antianginal efficacy and safety of controlled-delivery diltiazem qd versus an equivalent dose of immediate-release diltiazem tid. Cardiovasc Drugs Ther. 9:1995;319-330.
36. Frishman W.H., Glasser S., Stone P., Deedwania P.C., Johnson M., Fakouhi T.D. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol. 83:1999;507-514.
37. Veterans Affairs ACME Investigators, Parisi A.F., Folland E.D., Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 326:1992;10-16.
38. Henderson R.A., Pocock S.J., Clayton T.C., et al. Seven-year outcome in the RITA-2 trial Coronary angioplasty versus medical therapy. J Am Coll Cardiol. 42:2003;1161-1170.
39. Chaitman BR, Pepine CJ, Parker JO, et al., for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. A double-blind, randomized, placebo-controlled trial to assess the effects of ranolazine in combination with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 2004;291:309-16
40. Mark D.B., Hlatky M.A., Harrell F.E. Jr., et al. Exercise treadmill score for predicting prognosis in coronary disease. Ann Intern Med. 106:1987;793.